{"id":31808,"date":"2025-04-15T13:23:06","date_gmt":"2025-04-15T05:23:06","guid":{"rendered":"https:\/\/flcube.com\/?p=31808"},"modified":"2025-04-15T13:23:07","modified_gmt":"2025-04-15T05:23:07","slug":"zhuhai-beihai-biotech-gains-nmpa-clinical-clearance-for-innovative-peptide-drug-conjugate-bh259","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31808","title":{"rendered":"Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259"},"content":{"rendered":"\n<p>China-based Zhuhai Beihai Biotech Co., Ltd. has announced that it has received clinical trial clearance from the National Medical Products Administration (NMPA) for its peptide-drug conjugate (PDC) BH259. This milestone marks a significant step forward in the development of this innovative therapeutic candidate, which holds promise for the treatment of cancer.<\/p>\n\n\n\n<p><strong>Innovative Peptide-Drug Conjugate<\/strong><br>BH259 is a peptide-drug conjugate (PDC) developed with full intellectual property rights by Zhuhai Beihai Biotechnology. The compound combines a targeting peptide with a cytotoxic payload, designed to deliver toxins specifically to tumor cells while minimizing systemic toxicity. This mechanism enhances both efficacy and safety, addressing key challenges in oncology treatment.<\/p>\n\n\n\n<p><strong>Preclinical Success and Mechanism of Action<\/strong><br>Multiple preclinical studies have demonstrated BH259\u2019s robust anti-tumor activity and favorable safety profile. Animal efficacy trials indicate that BH259 effectively targets tumor cells and tissues, significantly increasing the therapeutic window of its payload toxins. Pharmacokinetic studies further confirm its ability to precisely deliver toxins to cancer cells, highlighting its potential as a next-generation oncology therapy.<\/p>\n\n\n\n<p><strong>Future Development and Market Potential<\/strong><br>With clinical trial clearance secured, Zhuhai Beihai Biotechnology is poised to advance BH259 into human trials, aiming to validate its safety and efficacy in patients. The successful development of BH259 could position the company as a leader in the emerging field of peptide-drug conjugates, offering new treatment options for patients with unmet medical needs.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Zhuhai Beihai Biotech Co., Ltd. has announced that it has received clinical trial clearance&#8230;<\/p>\n","protected":false},"author":1,"featured_media":31809,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,1717,16,62],"class_list":["post-31808","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-beihai-biotech","tag-cancer","tag-clinical-trial-approval-initiation"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Zhuhai Beihai Biotech Co., Ltd. has announced that it has received clinical trial clearance from the National Medical Products Administration (NMPA) for its peptide-drug conjugate (PDC) BH259. This milestone marks a significant step forward in the development of this innovative therapeutic candidate, which holds promise for the treatment of cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31808\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259\" \/>\n<meta property=\"og:description\" content=\"China-based Zhuhai Beihai Biotech Co., Ltd. has announced that it has received clinical trial clearance from the National Medical Products Administration (NMPA) for its peptide-drug conjugate (PDC) BH259. This milestone marks a significant step forward in the development of this innovative therapeutic candidate, which holds promise for the treatment of cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31808\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-15T05:23:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-15T05:23:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1503-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31808#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31808\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259\",\"datePublished\":\"2025-04-15T05:23:06+00:00\",\"dateModified\":\"2025-04-15T05:23:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31808\"},\"wordCount\":242,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31808#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1503-png.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Beihai Biotech\",\"Cancer\",\"Clinical trial approval \\\/ initiation\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31808#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31808\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31808\",\"name\":\"Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31808#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31808#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1503-png.webp\",\"datePublished\":\"2025-04-15T05:23:06+00:00\",\"dateModified\":\"2025-04-15T05:23:07+00:00\",\"description\":\"China-based Zhuhai Beihai Biotech Co., Ltd. has announced that it has received clinical trial clearance from the National Medical Products Administration (NMPA) for its peptide-drug conjugate (PDC) BH259. This milestone marks a significant step forward in the development of this innovative therapeutic candidate, which holds promise for the treatment of cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31808#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31808\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31808#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1503-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1503-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31808#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259 - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Zhuhai Beihai Biotech Co., Ltd. has announced that it has received clinical trial clearance from the National Medical Products Administration (NMPA) for its peptide-drug conjugate (PDC) BH259. This milestone marks a significant step forward in the development of this innovative therapeutic candidate, which holds promise for the treatment of cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31808","og_locale":"en_US","og_type":"article","og_title":"Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259","og_description":"China-based Zhuhai Beihai Biotech Co., Ltd. has announced that it has received clinical trial clearance from the National Medical Products Administration (NMPA) for its peptide-drug conjugate (PDC) BH259. This milestone marks a significant step forward in the development of this innovative therapeutic candidate, which holds promise for the treatment of cancer.","og_url":"https:\/\/flcube.com\/?p=31808","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-15T05:23:06+00:00","article_modified_time":"2025-04-15T05:23:07+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1503-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31808#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31808"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259","datePublished":"2025-04-15T05:23:06+00:00","dateModified":"2025-04-15T05:23:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31808"},"wordCount":242,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31808#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1503-png.webp","keywords":["ADC \/ XDC","Beihai Biotech","Cancer","Clinical trial approval \/ initiation"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31808#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31808","url":"https:\/\/flcube.com\/?p=31808","name":"Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31808#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31808#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1503-png.webp","datePublished":"2025-04-15T05:23:06+00:00","dateModified":"2025-04-15T05:23:07+00:00","description":"China-based Zhuhai Beihai Biotech Co., Ltd. has announced that it has received clinical trial clearance from the National Medical Products Administration (NMPA) for its peptide-drug conjugate (PDC) BH259. This milestone marks a significant step forward in the development of this innovative therapeutic candidate, which holds promise for the treatment of cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31808#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31808"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31808#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1503-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1503-png.webp","width":1080,"height":608,"caption":"Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31808#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1503-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31808","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31808"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31808\/revisions"}],"predecessor-version":[{"id":31810,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31808\/revisions\/31810"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31809"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31808"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31808"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31808"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}